Document Detail


Patients with atherosclerotic vascular disease: how low should plasma homocyst(e)ine levels go?
MedLine Citation:
PMID:  14728038     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Plasma homocyst(e)ine level is a strong independent risk factor for vascular disease. The spelling of homocyst(e)ine reflects that what is measured, and what constitutes the risk factor; it includes homocysteine, homocystine (the dimer of homocysteine) and mixed cysteine-homocysteine disulfide. Homocyst(e)ine levels above 10.2 micro mol/L are associated with a doubling of coronary risk, and levels above 20 micro mol/L are associated with a 9.9-fold increase in risk compared with levels below 9 micro mol/L. The mechanisms by which homocyst(e)ine promotes vascular disease include increased thrombosis, consumption of nitric oxide, endothelial injury, and reduced thrombolysis. Homocyst(e)ine is an independent predictor of carotid atherosclerosis. Vitamin therapy with folate, pyridoxine (vitamin B(6)), and cyanocobalamin (vitamin B(12)) reduces blood levels of homocyst(e)ine, improves endothelial function, reduces levels of fibrinogen and lipoprotein(a), improves thrombolysis, and in uncontrolled clinical observation, leads to regression of carotid plaque. These lines of evidence support a causal relationship between homocyst(e)ine and atherosclerosis, and suggest that in patients with vascular disease, an appropriate target level for therapy may be below 9 or 10 micro mol/L. Randomized controlled studies are under way to determine whether vitamin therapy is effective in secondary prevention of myocardial infarction and stroke.
Authors:
J D Spence
Related Documents :
8873668 - The asp9 asn mutation in the lipoprotein lipase gene is associated with increased progr...
1751258 - Ischemic heart disease, serum cholesterol, and apolipoproteins in capd.
25231508 - Effect of spironolactone on diastolic function in hypertensive left ventricular hypertr...
16690338 - Beginning to end: cardiovascular implications of growth hormone (gh) deficiency and gh ...
18375968 - Electrical storm in a patient with arrhythmogenic right ventricular cardiomyopathy and ...
16639318 - Predictors of neurocognitive decline after carotid endarterectomy.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  American journal of cardiovascular drugs : drugs, devices, and other interventions     Volume:  1     ISSN:  1175-3277     ISO Abbreviation:  Am J Cardiovasc Drugs     Publication Date:  2001  
Date Detail:
Created Date:  2004-01-19     Completed Date:  2004-04-08     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100967755     Medline TA:  Am J Cardiovasc Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  85-9     Citation Subset:  IM    
Affiliation:
Stroke Prevention and Atherosclerosis Research Centre, Siebens-Drake/Robarts Research Institute, London, Ontario, Canada. dspence@rri.on.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Arteriosclerosis / blood*,  drug therapy,  prevention & control*
Clinical Trials as Topic
Dipeptides / blood*
Folic Acid / therapeutic use
Homocysteine / blood*
Homocystine / blood*
Humans
Pyridoxine / therapeutic use
Risk Factors
Vitamin B 12 / therapeutic use
Chemical
Reg. No./Substance:
0/Dipeptides; 454-28-4/Homocysteine; 462-10-2/Homocystine; 4985-47-1/cysteinylhomocysteine mixed disulfide; 59-30-3/Folic Acid; 65-23-6/Pyridoxine; 68-19-9/Vitamin B 12

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  New strategies to prevent restenosis.
Next Document:  Pharmacologic management of arrhythmias in patients with congenital heart disease.